Administration of selective inhibitors of nuclear transport (SINE) such as Selinexor, have led to an enrichment of tumor suppressor proteins in the nucleus.25 This subsequently resulted in apoptosis, reduction of tumor spreading and improved overall survival in preclinical models in PCa.26, 27, 28 Clinical studies are being performed to reveal the real potential of XPO1‐directed therapy. The gene discussed is XPO1; the disease is posterior cortical atrophy.